The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
What we do
Know AML is the first global education and awareness initiative that provides patients and caregivers with the information, resources, and support they need to deal with acute myeloid leukemia.
Our Vision
Know AML aspires to facilitate and improve acute myeloid leukemia knowledge worldwide and develop community-based initiatives to overcome current and future challenges.
Our Mission
The mission of Know AML is to drive education and awareness of acute myeloid leukemia globally through community collaborations, while continuing to raise awareness of the resources and support currently available.
Our Strategy
Know AML have identified a number of activities that fall within three key areas: awareness, education, and engagement.
Acute Myeloid Leukemia World Awareness Day and Blood Cancer Awareness Month remain our core awareness raising focal points, alongside other internationally recognized events targeting the healthcare community.
In 2021–2022, Know AML will continue to educate the patient and caregiver community on the latest treatment advances in acute myeloid leukemia. This will involve providing updates on what the healthcare and scientific community are talking about in the field of acute myeloid leukemia, including discussions on real-world evidence and survival information.
Know AML will also communicate, in patient-friendly formats, the terminology used by the healthcare and scientific community that is relevant to acute myeloid leukemia, so that patients and caregivers can understand and act on the information they receive.
In 2022–2023, Know AML will also start to examine broader quality of life issues, including supportive care, the relationship between mental health and acute myeloid leukemia, and exploring the patient journey.
Collaboration
Know AML was founded in partnership with CancerCare in 2017 and, since 2023, runs in collaboration with ALAN. ALAN is an independent global network of patient organizations, dedicated to changing outcomes of patients with acute leukemia by strengthening patient advocacy in that area. It aims to build capacity in the members of the network to deliver tailored services to patients with acute leukemia and their caregivers on the national level, while joining forces between organizations on the policy and research level across countries.
Scientific Education Support
Know AML is brought to you by Scientific Education Support (SES). SES loves nothing more than building networks and working with communities to facilitate education through collaboration, ensuring that patients have access to the latest information, support, and treatment options. SES assists the ambassador group by handling the day-to-day running of the initiative, which includes content generation, everyday management, and keeping the Know AML website up to date.
Rare Diseases International
Know AML is proud to be connected with Rare Diseases International (RDI). RDI provides a strong common voice for persons living with a rare disease and their families around the world, covering all rare diseases. Know AML is a stakeholder of RDI and part of the RDI community.